December 6th, 2018: Chicago, IL
Executive Director, Vanessa Vogel-Falrley, attended the Angelman Biomarkers and Outcome Measures Alliance. (the A-BOM) is an alliance formed by both the Foundation for Angelman Syndrome Therapeutics and the Angelman Syndrome Foundation, together with researchers and pharmaceutical corporations to help move new treatments to the clinical trial phase.
Just like Angelman Syndrome we need rigorous ways to measure if these treatments improve the quality of life for patients and families. The Dup15q Alliance is committed to working with groups like ABOM to drive this area of biomarkers forward as fast as possible. At this meeting the ABOM members shared data, research, medical findings and the status of their clinical trials.